vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Smith Douglas Homes Corp. (SDHC). Click either name above to swap in a different company.
Smith Douglas Homes Corp. is the larger business by last-quarter revenue ($260.4M vs $139.2M, roughly 1.9× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 1.4%, a 34.1% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -9.4%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $8.7M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 17.3%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
ADMA vs SDHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $260.4M |
| Net Profit | $49.4M | $3.5M |
| Gross Margin | 63.8% | 19.9% |
| Operating Margin | 45.1% | 6.5% |
| Net Margin | 35.5% | 1.4% |
| Revenue YoY | 18.4% | -9.4% |
| Net Profit YoY | -55.9% | -14.3% |
| EPS (diluted) | $0.20 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $260.4M | ||
| Q3 25 | $134.2M | $262.0M | ||
| Q2 25 | $122.0M | $223.9M | ||
| Q1 25 | $114.8M | $224.7M | ||
| Q4 24 | $117.5M | $287.5M | ||
| Q3 24 | $119.8M | $277.8M | ||
| Q2 24 | $107.2M | $220.9M | ||
| Q1 24 | $81.9M | $189.2M |
| Q4 25 | $49.4M | $3.5M | ||
| Q3 25 | $36.4M | $2.1M | ||
| Q2 25 | $34.2M | $2.4M | ||
| Q1 25 | $26.9M | $2.7M | ||
| Q4 24 | $111.9M | $4.1M | ||
| Q3 24 | $35.9M | $5.3M | ||
| Q2 24 | $32.1M | $3.6M | ||
| Q1 24 | $17.8M | $3.0M |
| Q4 25 | 63.8% | 19.9% | ||
| Q3 25 | 56.3% | 21.0% | ||
| Q2 25 | 55.1% | 23.2% | ||
| Q1 25 | 53.2% | 23.8% | ||
| Q4 24 | 53.9% | 25.5% | ||
| Q3 24 | 49.8% | 26.5% | ||
| Q2 24 | 53.6% | 26.7% | ||
| Q1 24 | 47.8% | 26.1% |
| Q4 25 | 45.1% | 6.5% | ||
| Q3 25 | 38.0% | 6.6% | ||
| Q2 25 | 35.1% | 7.7% | ||
| Q1 25 | 30.4% | 8.7% | ||
| Q4 24 | 32.6% | 10.4% | ||
| Q3 24 | 33.1% | 14.2% | ||
| Q2 24 | 36.6% | 11.7% | ||
| Q1 24 | 26.7% | 11.3% |
| Q4 25 | 35.5% | 1.4% | ||
| Q3 25 | 27.1% | 0.8% | ||
| Q2 25 | 28.1% | 1.1% | ||
| Q1 25 | 23.4% | 1.2% | ||
| Q4 24 | 95.2% | 1.4% | ||
| Q3 24 | 30.0% | 1.9% | ||
| Q2 24 | 29.9% | 1.7% | ||
| Q1 24 | 21.7% | 1.6% |
| Q4 25 | $0.20 | $0.39 | ||
| Q3 25 | $0.15 | $0.24 | ||
| Q2 25 | $0.14 | $0.26 | ||
| Q1 25 | $0.11 | $0.30 | ||
| Q4 24 | $0.45 | $0.50 | ||
| Q3 24 | $0.15 | $0.58 | ||
| Q2 24 | $0.13 | $0.40 | ||
| Q1 24 | $0.08 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $12.7M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $86.7M |
| Total Assets | $624.2M | $557.6M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $12.7M | ||
| Q3 25 | $61.4M | $14.8M | ||
| Q2 25 | $90.3M | $16.8M | ||
| Q1 25 | $71.6M | $12.7M | ||
| Q4 24 | $103.1M | $22.4M | ||
| Q3 24 | $86.7M | $23.7M | ||
| Q2 24 | $88.2M | $17.3M | ||
| Q1 24 | $45.3M | $32.8M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $86.7M | ||
| Q3 25 | $431.2M | $82.2M | ||
| Q2 25 | $398.3M | $80.0M | ||
| Q1 25 | $373.4M | $76.9M | ||
| Q4 24 | $349.0M | $73.6M | ||
| Q3 24 | $231.9M | $68.4M | ||
| Q2 24 | $188.3M | $62.1M | ||
| Q1 24 | $153.7M | $59.7M |
| Q4 25 | $624.2M | $557.6M | ||
| Q3 25 | $568.7M | $571.6M | ||
| Q2 25 | $558.4M | $570.2M | ||
| Q1 25 | $510.6M | $513.9M | ||
| Q4 24 | $488.7M | $475.9M | ||
| Q3 24 | $390.6M | $460.1M | ||
| Q2 24 | $376.4M | $429.3M | ||
| Q1 24 | $350.9M | $401.3M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $9.8M |
| Free Cash FlowOCF − Capex | $34.6M | $8.7M |
| FCF MarginFCF / Revenue | 24.8% | 3.4% |
| Capex IntensityCapex / Revenue | 0.8% | 0.4% |
| Cash ConversionOCF / Net Profit | 0.72× | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $9.8M | ||
| Q3 25 | $13.3M | $22.8M | ||
| Q2 25 | $21.1M | $-28.9M | ||
| Q1 25 | $-19.7M | $-34.9M | ||
| Q4 24 | $50.2M | $5.5M | ||
| Q3 24 | $25.0M | $22.9M | ||
| Q2 24 | $45.6M | $39.0K | ||
| Q1 24 | $-2.2M | $-9.3M |
| Q4 25 | $34.6M | $8.7M | ||
| Q3 25 | $-1.1M | $21.4M | ||
| Q2 25 | $18.7M | $-31.1M | ||
| Q1 25 | $-24.4M | $-35.9M | ||
| Q4 24 | $47.5M | $4.8M | ||
| Q3 24 | $24.0M | $22.3M | ||
| Q2 24 | $43.6M | $-2.1M | ||
| Q1 24 | $-4.6M | $-9.7M |
| Q4 25 | 24.8% | 3.4% | ||
| Q3 25 | -0.8% | 8.2% | ||
| Q2 25 | 15.3% | -13.9% | ||
| Q1 25 | -21.2% | -16.0% | ||
| Q4 24 | 40.4% | 1.7% | ||
| Q3 24 | 20.0% | 8.0% | ||
| Q2 24 | 40.7% | -1.0% | ||
| Q1 24 | -5.6% | -5.1% |
| Q4 25 | 0.8% | 0.4% | ||
| Q3 25 | 10.7% | 0.5% | ||
| Q2 25 | 2.0% | 0.9% | ||
| Q1 25 | 4.1% | 0.5% | ||
| Q4 24 | 2.3% | 0.2% | ||
| Q3 24 | 0.9% | 0.2% | ||
| Q2 24 | 1.9% | 1.0% | ||
| Q1 24 | 2.9% | 0.2% |
| Q4 25 | 0.72× | 2.77× | ||
| Q3 25 | 0.36× | 10.70× | ||
| Q2 25 | 0.62× | -12.24× | ||
| Q1 25 | -0.73× | -13.01× | ||
| Q4 24 | 0.45× | 1.33× | ||
| Q3 24 | 0.70× | 4.28× | ||
| Q2 24 | 1.42× | 0.01× | ||
| Q1 24 | -0.12× | -3.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
SDHC
| Southeast | $164.7M | 63% |
| Central | $95.8M | 37% |
